Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised Trials
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Mild cognitive impairment (MCI) refers to a transitional zone between normal ageing and dementia. Despite the uncertainty regarding the definition of MCI as a clinical entity, clinical trials have been conducted in the attempt to study the role of cholinesterase inhibitors (ChEIs) currently approved for symptomatic treatment of mild to moderate Alzheimer disease (AD), in preventing progression from MCI to AD. The objective of this review is to assess the effects of ChEIs (donepezil, rivastigmine, and galantamine) in delaying the conversion from MCI to Alzheimer disease or dementia. METHODS AND FINDINGS: The terms "donepezil", "rivastigmine", "galantamine", and "mild cognitive impairment" and their variants, synonyms, and acronyms were used as search terms in four electronic databases (MEDLINE, EMBASE, Cochrane, PsycINFO) and three registers: the Cochrane Collaboration Trial Register, Current Controlled Trials, and ClinicalTrials.gov. Published and unpublished studies were included if they were randomized clinical trials published (or described) in English and conducted among persons who had received a diagnosis of MCI and/or abnormal memory function documented by a neuropsychological assessment. A standardized data extraction form was used. The reporting quality was assessed using the Jadad scale. Three published and five unpublished trials met the inclusion criteria (three on donepezil, two on rivastigmine, and three on galantamine). Enrolment criteria differed among the trials, so the study populations were not homogeneous. The duration of the trials ranged from 24 wk to 3 y. No significant differences emerged in the probability of conversion from MCI to AD or dementia between the treated groups and the placebo groups. The rate of conversion ranged from 13% (over 2 y) to 25% (over 3 y) among treated patients, and from 18% (over 2 y) to 28% (over 3 y) among those in the placebo groups. Only for two studies was it possible to derive point estimates of the relative risk of conversion: 0.85 (95% confidence interval 0.64-1.12), and 0.84 (0.57-1.25). Statistically significant differences emerged for three secondary end points. However, when adjusting for multiple comparisons, only one difference remained significant (i.e., the rate of atrophy in the whole brain). CONCLUSIONS: The use of ChEIs in MCI was not associated with any delay in the onset of AD or dementia. Moreover, the safety profile showed that the risks associated with ChEIs are not negligible. The uncertainty regarding MCI as a clinical entity raises the question as to the scientific validity of these trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is notable that a widely used treatment strategy for Alzheimer’s disease is to increase brain acetylcholine levels (reviewed in ref. 48).”
From Amyloid beta from axons and dendrites reduces local spine number and plasticity (2010) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
What Makes Clinical Research Ethical?
Emanuel, E. J. (2000) · JAMA · doi:10.1001/jama.283.20.2701 · Cited by 2,710
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 10×
“The description of the randomization process was adequate in only one trial [37].”
BackgroundMethodResultInfluentialCummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
Mild Cognitive Impairment as a Clinical Entity and Treatment Target
Petersen, R. C., & Morris, J. C. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1160 · Cited by 935 · cited 1×
“Nevertheless, the suitability of using ChEIs to treat persons labelled with MCI continues to be widely debated [23–26].”
BackgroundMoynihan, R., G⊘tzsche, P. C., Heath, I., & Henry, D. (2002) · BMJ · doi:10.1136/bmj.324.7342.886 · Cited by 900
Cited by
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Review Article: Genetics of Alzheimer Disease
Bekris, L. M., Yu, C.-E., Bird, T. D., & Tsuang, D. W. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383571 · Cited by 1,029
“Treatment of AD with cholinesterase inhibitors and memantine may result in slowing of cognitive decline in patients with mildto-moderate dementia, but current treatments do not modify the course of illness.(11,12)”
Resistance Training and Executive Functions: A 12-Month Randomized Controlled Trial
Liu-Ambrose, T. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.494 · Cited by 775
Plassman, B. L., Williams, J. W., Burke, J. R., Holsinger, T., & Benjamin, S. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-3-201008030-00258 · Cited by 681
Learning, Attentional Control, and Action Video Games
Green, C. S., & Bavelier, D. (2012) · Current Biology · doi:10.1016/j.cub.2012.02.012 · Cited by 679
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579
“Unfortunately, clinical trials based on long-term administration of cholinesterase inhibitors to patients with Mild Cognitive Impairment resulted in failure to reduce the risk or delay the onset of Alzheimer's disease (Raschetti et al., 2007; Contestabile, 2011).”
Blumenthal, J. A. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.470 · Cited by 578
EFNS guidelines for the diagnosis and management of Alzheimer's disease
Hort, J., O’Brien, J. T., Gainotti, G., Pirttila, T., Popescu, B. O., Rektorova, I., Sorbi, S., Scheltens, P., & Dementia, O. B. O. T. E. S. P. O. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03040.x · Cited by 490
Sanford, A. M. (2017) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2017.02.005 · Cited by 436
Olivares, D., K. Deshpande, V., Shi, Y., K. Lahiri, D., H. Greig, N., T. Rogers, J., & Huang, X. (2012) · Current Alzheimer Research · doi:10.2174/156720512801322564 · Cited by 407
Inflammation and Alzheimer’s disease
Lee, Y.-J., Han, S. B., Nam, S.-Y., Oh, K.-W., & Hong, J. T. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1006-7 · Cited by 396
Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift
Golde, T. E., Schneider, L. S., & Koo, E. H. (2011) · Neuron · doi:10.1016/j.neuron.2011.01.002 · Cited by 382
The history of the cholinergic hypothesis
Contestabile, A. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.12.044 · Cited by 374
Amyloid beta from axons and dendrites reduces local spine number and plasticity
Wei, W., Nguyen, L. N., Kessels, H. W., Hagiwara, H., Sisodia, S., & Malinow, R. (2010) · Nature Neuroscience · doi:10.1038/nn.2476 · Cited by 357
Jean, L., Bergeron, M.-È., Thivierge, S., & Simard, M. (2010) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181c37ce9 · Cited by 337
Hersi, M., Irvine, B., Gupta, P., Gomes, J., Birkett, N., & Krewski, D. (2017) · NeuroToxicology · doi:10.1016/j.neuro.2017.03.006 · Cited by 332
Lewczuk, P., Riederer, P., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramirez, A., Parnetti, L., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 307
Gill, S. S., Anderson, G. M., Fischer, H. D., Bell, C. M., Li, P., Normand, S.-L. T., & Rochon, P. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.43 · Cited by 306
Sinn, N., Milte, C. M., Street, S. J., Buckley, J. D., Coates, A. M., Petkov, J., & Howe, P. R. C. (2012) · British Journal of Nutrition · doi:10.1017/s0007114511004788 · Cited by 297
Effects of Ginkgo biloba in dementia: systematic review and meta-analysis
Weinmann, S., Roll, S., Schwarzbach, C., Vauth, C., & Willich, S. N. (2010) · BMC Geriatrics · doi:10.1186/1471-2318-10-14 · Cited by 297
Twine, N. A., Janitz, K., Wilkins, M. R., & Janitz, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016266 · Cited by 288
Köse, L. P., Gülçin, İ., Gören, A. C., Namiesnik, J., Martinez-Ayala, A. L., & Gorinstein, S. (2015) · Industrial Crops and Products · doi:10.1016/j.indcrop.2015.05.034 · Cited by 271
Papp, K. V., Walsh, S. J., & Snyder, P. J. (2009) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2008.10.008 · Cited by 269
Modifiable Risk Factors for Alzheimer’s Disease
Edwards III, G. A., Gamez, N., Escobedo Jr., G., Calderon, O., & Moreno-Gonzalez, I. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00146 · Cited by 253
Fluid Biomarkers in Alzheimer Disease
Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208
“Clinical MCI trials of cholinesterase inhibitors, in which having a reduced conversion rate to AD was used as a clinical endpoint, have failed to find any significant benefit of the drugs (Raschetti et al. 2007).”
MethodSosa, A. L., Albanese, E., Stephan, B. C. M., Dewey, M., Acosta, D., Ferri, C. P., Guerra, M., Huang, Y., Jacob, K. S., Jiménez-Velázquez, I. Z., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001170 · Cited by 201
“Although, there have been controversies surrounding the MCI entity itself [55–58], they have not to our knowledge focused on the 1.”
Self-citationThe Therapeutic Potential of Rosemary (Rosmarinus officinalis) Diterpenes for Alzheimer’s Disease
Habtemariam, S. (2016) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2016/2680409 · Cited by 191
“, rivastigmine, galantamine, tacrine, and donepezil) andN-methyl-Daspartate (NMDA) receptor antagonist (memantine) which have some benefit in alleviating the clinical symptoms of AD [35].”
BackgroundReimagining cholinergic therapy for Alzheimer’s disease
Giacobini, E., Cuello, A. C., & Fisher, A. (2022) · Brain · doi:10.1093/brain/awac096 · Cited by 187
Cicchese, J. J., & Berry, S. D. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00001 · Cited by 174
Lam, L. C.-W., Chan, W. C., Leung, T., Fung, A. W.-T., & Leung, E. M.-F. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118173 · Cited by 174
“[2,3] It is therefore not surprising to see an increasing interest in the research on modifiable lifestyle factors that are suggested by epidemiological data to be potentially protective against cognitive decline.”
Lin, W.-T., Chen, R.-C., Lu, W.-W., Liu, S.-H., & Yang, F.-Y. (2015) · Scientific Reports · doi:10.1038/srep09671 · Cited by 172
Topal, M., Gocer, H., Topal, F., Kalin, P., Köse, L. P., Gülçin, İ., Çakmak, K. C., Küçük, M., Durmaz, L., Gören, A. C., et al. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2015.1018244 · Cited by 169
Cognition enhancers between treating and doping the mind
Lanni, C., Lenzken, S. C., Pascale, A., Del Vecchio, I., Racchi, M., Pistoia, F., & Govoni, S. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.02.004 · Cited by 166
“[15] Raschetti R, Albanese E, Vanacore N, Maggini M.”
BackgroundHerukka, S.-K., Simonsen, A. H., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.009 · Cited by 141
Morimoto, B. H., Schmechel, D., Hirman, J., Blackwell, A., Keith, J., Gold, M., & on behalf of the AL-108-211 Study Investigators (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000348347 · Cited by 115
Browne, G., Berry, E., Kapur, N., Hodges, S., Smyth, G., Watson, P., & Wood, K. (2011) · Memory · doi:10.1080/09658211.2011.614622 · Cited by 92
“While the effectiveness of pharmacological interventions has yet to be conclusively demonstrated in AD and MCI populations (Raschetti, Albanese, Vanacore, & Maggini, 2007 ), there are an increasing number of non-medical interventions that may provide a suitable alternative.”
BackgroundKurz, A. F., Leucht, S., & Lautenschlager, N. T. (2011) · International Psychogeriatrics · doi:10.1017/s1041610211001001 · Cited by 82
“, 2008) and the absence of pharmacological therapies for mild cognitive impairment (MCI) (Raschetti et al., 2007) have heightened interest in non-pharmacological”
BackgroundShen, F., Smith, J. A. M., Chang, R., Bourdet, D. L., Tsuruda, P. R., Obedencio, G. P., & Beattie, D. T. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.026 · Cited by 79
Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer’s disease
Richter, N., Beckers, N., Onur, O. A., Dietlein, M., Tittgemeyer, M., Kracht, L., Neumaier, B., Fink, G. R., & Kukolja, J. (2018) · Brain · doi:10.1093/brain/awx356 · Cited by 77
“While some studies suggested that acetylcholinester- ase (AChE) inhibitors may lower the rate of progression from MCI to dementia (Petersen et al., 2005; Diniz et al., 2009), meta-analyses did not confirm this finding (Birks and Flicker, 2006; Loy and Schneider, 2006; Raschetti et al., 2007).”
BackgroundResultShamsi, A., Mohammad, T., Anwar, S., Alajmi, M. F., Hussain, A., Hassan, M. I., Ahmad, F., & Islam, A. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.01.134 · Cited by 73
Brum, P. S., Forlenza, O. V., & Yassuda, M. S. (2009) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642009dn30200010 · Cited by 67
“Studies have shown pharmacologic intervention with cholinesterase inhibitors to be largely ineffective in delaying progression to dementias.(8,9) The MCI concept has led to debate regarding the value of non-pharmacologic interventions in pre-clinical stages of dementias.”
BackgroundUnified theory of Alzheimer’s disease (UTAD): implications for prevention and curative therapy
Nehls, M. (2016) · Journal of Molecular Psychiatry · doi:10.1186/s40303-016-0018-8 · Cited by 41
“[583].”
Abd El-Aziz, N. M. A., Shehata, M. G., Alsulami, T., Badr, A. N., Elbakatoshy, M. R., Ali, H. S., & El-Sohaimy, S. A. (2022) · Pharmaceuticals · doi:10.3390/ph16010012 · Cited by 31
“These synthetic drugs are associated with a number of side effects, possess much economic burden and are not implemented for all cases of AD [13].”
Background
Metadata
- Authors
- Raschetti, R., Albanese, E., Vanacore, N., & Maggini, M.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-11-27
- Volume
- 4
- Issue
- 11
- Pages
- e338
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2049890856
- Cited by
- 321
- References
- 33
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.